Navigation Links
Genelabs Technologies Announces Presentation of Data on,Non-Nucleoside HCV Polymerase Inhibitor at 20th International,Conference on Antiviral Research Meeting

llaboration with Novartis covering Genelabs' non-nucleoside HCV polymerase inhibitors.

"The data presented today clearly support the further investigation of non-nucleoside polymerase inhibitors for the future treatment of HCV infection," said Ronald C. Griffith, Ph.D., Genelabs' Chief Scientific Officer. "Furthermore, we believe future treatment of HCV is likely to involve combinations of antiviral drugs and these data suggest that combinations of this type of non-nucleoside agent with interferon or other likely therapeutic drugs, such as nucleoside chain terminators or protease inhibitors, may be feasible."

About Genelabs Technologies

Genelabs Technologies, Inc. is a biopharmaceutical company focused on the discovery and development of pharmaceutical products to improve human health. We have built drug discovery capabilities that can support various research and development projects. Genelabs is currently concentrating these capabilities on discovering novel compounds that selectively inhibit replication of the hepatitis C virus and advancing preclinical development of compounds from this hepatitis C virus drug discovery program, while also developing a late-stage product for lupus. We believe that these high-risk, potentially high reward programs focus our research and development expertise in areas where we have the opportunity to generate either first-in-class or best-in-class products that will address diseases for which current therapies are inadequate. For more information, please visit www.genelabs.com.

NOTE: Genelabs(R) and the Genelabs logo are registered trademarks and Prestara(TM) is a trademark of Genelabs Technologies, Inc.

NOTE ON FORWARD LOOKING STATEMENTS AND RISKS: This press release contains forward-looking statements including statements on the feasibility of non-nucleoside polymerase inhibitors for the future treatment of HCV infection and the prospects fo
'"/>




Page: 1 2 3

Related medicine technology :

1. Neose Technologies to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
3. Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide
4. Palatin Technologies and King Pharmaceuticals Announce Plan To Present Results of Bremelanotide Phase 2b Studies in Men With Erectile Dysfunction
5. Micell Technologies Presents Data on Novel Drug-Eluting Stents
6. OncoGenex Technologies Announces Phase II Data of OGX-011 in Metastatic Breast Cancer at American Association for Cancer Research 2007 Annual Meeting
7. AVAX Technologies Presents Results of Phase I-II M-Vax Trial at Annual Meeting of American Association for Cancer Research
8. Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery of GLP-1 and PYY
9. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
10. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
Post Your Comments:
(Date:4/17/2015)... , April 17, 2015  Healthcare reform ... of many new forms of provider networks, such ... Organizations (ACOs). The rapid evolution of these networks ... their access, pricing and service delivery systems to ... To help the pharma sector adapt to ...
(Date:4/17/2015)... 2015 Research and Markets ( ... "Medical Device Outsourcing - Global Strategic Business ... This report analyzes the worldwide markets for Medical ... Device Categories: Class I, Class II, and Class ... report Include - Radiology, Orthopedic, Neurology, Cardiology, and ...
(Date:4/17/2015)... 17, 2015  Trovagene, Inc., (NASDAQ:  TROV) a ... clinical data presented at the 2015 European Lung ... Cancer Monitoring ℠ (PCM) platform outperformed tissue ... EGFR T790M mutations in metastatic lung cancer ... T790M Mutation in Urinary Circulating Tumor DNA from ...
Breaking Medicine Technology:Pharmaceutical Industry Struggling to Better Serve Provider Networks Such as Accountable Care Organizations (ACOs) 2Medical Device Outsourcing (Radiology, Orthopedic, Neurology, Cardiology, and Others) Market 2015 - Global Strategic Business Report 2Medical Device Outsourcing (Radiology, Orthopedic, Neurology, Cardiology, and Others) Market 2015 - Global Strategic Business Report 3Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 2Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 3Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 4
... BETHESDA, Md., April 14 Micromet, Inc.,(Nasdaq: ... novel, proprietary,antibodies for the treatment of cancer, ... meeting of the American Association for,Cancer Research ... that commercial,anti-cancer antibodies trastuzumab (Herceptin(R); Genentech, Roche),cetuximab ...
... the, Tumor Suppressor P53 Inhibited Tumor Growth Synergistically in Preclinical ... ... 14 ,Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) announced today that ... 2008 Annual Meeting of the American Association for Cancer Research,(AACR) further ...
Cached Medicine Technology:Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 2Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 3Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 4Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 5Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting Antibodies 2Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting Antibodies 3Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting Antibodies 4
(Date:4/18/2015)... 18, 2015 Patients who undergo radiation ... mesothelioma later in life, but the disease is likely ... is unrelated to radiation. Surviving Mesothelioma has just posted ... Click here to read it now. , ... cases of 45 patients who had both a hematologic ...
(Date:4/18/2015)... In the past few weeks, TheBeautyPlace.com has been ... had to run maintenance on our shipping facilities to ... the PR Director. "It disrupted our regular shipping schedule ... back on track after having completed the maintenance." , ... systems which has not allowed some calls to come ...
(Date:4/18/2015)... On April 14th, 2015, Symantec released Volume ... say, “exposes a tactical shift by cyberattackers.” With everything from ... in 2014 - almost a million a day - to ... identified and patched by prominent manufacturers – as long as ... in a digital world can be fraught with peril, and ...
(Date:4/18/2015)... 18, 2015 “ ArcAngel ” was featured ... a look at the latest and coolest applications ... the host of AppWatch and technology expert, conducted the app ... safety app. , In a turbulent world, people may ... 911 should always be their first move, but some situations ...
(Date:4/18/2015)... 18, 2015 French physician and gastronome ... choices when he uttered, “Tell me what you eat, ... food to cope with stress or sadness has often ... indicates otherwise. Data collected from their Emotional ... to emotional eating, but for different reasons. , Collecting ...
Breaking Medicine News(10 mins):Health News:New Study Examines Relationship Between Radiation for Hematologic Cancers and Development of Mesothelioma, According to Surviving Mesothelioma 2Health News:TheBeautyPlace.com Temporary Number Available 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 3Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 4Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 5Health News:A Personal Safety Application was Featured on NewsWatch Television 2Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 2Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 3Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 4Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 5Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 6
... A new poll by Irishhealth.com has indicated the meager ... hospitals in the Irish Health Service. //Only one among ... ,The 40-bed Whitfield Clinic in Waterford and the 183-bed ... in healthcare. Of the registered users who were queried, ...
... new website launched to give online support to people ... 'Our Choices in Mental Health', the new national framework ... local level. // ,The Department of Health ... with these measures. The report, Our Choices in Mental ...
... study, the risk of developing pancreatic cancer increases by 90% with ... cancer risk was 70% higher in people who added sugar to ... compared with those who added no sugar. ,In spite ... it is for the first time that researchers have shown a ...
... of a controversial shake-up of hospital services in east Lancashire ... // ,East Lancashire Hospitals NHS Trust has ... A&E department that will now not be referred to the ... the decision that they have taken has granted the trust ...
... anti-polio drive Sunday even as new polio cases - three in ... ,During the drive, pulse polio drops would be administered to nearly ... to health officials here. , ,The latest case of ... 4 when Ajay, a 19-month-old baby in Jhabua district, was found ...
... Journal Of American Medical Association announced that having high blood ... In fact a theory by Dr. Mihai Gheorghiade of Northwestern ... blood to be viewed in new light. ,Dr. ... admission if a patient with heart failure continues to have ...
Cached Medicine News:Health News:New Website For People With Mental Problems 2Health News:Fury over Backing of Health Shake-up 2
The rotating stage assembly is designed to give the researcher maximum flexibility in the mounting of specimens. It can be turned to any horizontal and vertical angle via a ball joint mounting arran...
Punch set for Advanced Tissue Arrayer, 2.0 mm...
Inquire...
Inquire...
Medicine Products: